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Statement of Translational Relevance
Our study identifies HIF-1α as a key instigator of tumor immune adaptation, even under conditions of normal oxygen tension. We discovered that HIF-1α mediates immune adaptation through VEGFAdependent activation of the AKT and ERK signaling pathways. Therefore, our study suggests that pharmacologic blockade of HIF-1α or these associated signaling pathways may represent an effective strategy for the clinical management of cancer, particularly in combination with immune-based modalities.
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Introduction
Immunotherapy has emerged as a promising approach for the clinical management of cancer. However, in many cases, it has been observed that the generation of a tumor-specific immune response does not translate into tumor regression in cancer patients. A potential explanation for this is the overexpression by tumor cells of proteins that bestow them with enhanced survival, proliferation, and invasion capacity (1) . In particular, hypoxia-inducible factor 1 (HIF-1) is a key orchestrator of diverse biochemical pathways, from proliferation and survival to angiogenesis and invasion (2) . Overexpression of HIF-1 has been reported in virtually most of carcinomas (3) , and HIF-1 has been shown to drive cancer progression as well as resistance to chemotherapy and radiotherapy (2) . Moreover, resistance of tumor cells to killing by NK cells or T cells has been reported to occur through HIF-1 under hypoxia (4) (5) (6) (7) (8) (9) . Although HIF-1 is a gateway to cancer progression, the manner in which it initially arises within tumor cells remains unknown. In fact, HIF-1 is exquisitely sensitive to oxygen tension and is typically only present in stable form under hypoxia (10) . Here we found unexpectedly that stable expression of HIF-1 in tumor cells occurs even under normal oxygen tension. We inferred that gain of HIF-1 is a key element of cancer evolution that arises from selection pressure imposed by an antitumor immune response.
To explore this idea, we examined cancer evolution in the context of immune surveillance. Adaptation to immune defenses, in particular those mounted by CD8 + cytotoxic T lymphocytes (CTLs), has emerged as an early, indispensable, and host-intrinsic event in cancer progression (11) . Thus, immune surveillance is an ideal selection pressure for the analysis of cancer evolution. We invented a system referred to as VICE, for Vaccination-Induced Cancer Evolution, in which variants of a parental tumor are derived through serial rounds of immune selection either in culture or in mice (12) .
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We employed VICE to explore the role of HIF-1 in cancer evolution under immune surveillance. Here we show that the α subunit of HIF-1 (HIF-1α) becomes markedly elevated during immune selection even under normoxia, and HIF-1α expression by tumor cells dictates the ability of cognate CTLs to control tumor growth. To our knowledge, gain of HIF-1 in tumor cells under normoxia in response to immune selection has not been previously reported. We found that the effects of HIF-1α on immune adaptation are transmitted through vascular endothelial growth factor A (VEGFA)-mediated activation of the AKT and ERK pathways, which induce the expression of a constellation of anti-apoptotic molecules in tumor cells. Blockade of each of these pathways abrogated resistance of tumor cells to lysis by cognate CTLs, underscoring the importance of the HIF-1α/VEGFA axis in immune adaptation.
Materials and Methods
Cells. HPV-16 E7
+ cells (TC-1, TC-1 P3, TC-1 P3 (A17), TC-1/no insert, and TC-1/ HIF-1α) were used as a mouse tumor model. The production and maintenance of TC-1 (13) and TC-1 P3 A17 cells (14, 15) has been described previously. TC-1/HIF-1α cells were generated with the pMSCV/HIF-1α K532R vector (for TC-1/HIF-1α). For the production of human immune-resistant tumor cells, 10 6 CaSki (CaSki P0) cells were pulsed with 10 μg/ml HLA-A2-restricted MART-1 M27 peptide (AAGIGILTV) for 2 hr and mixed with KKM MART-1-specific human CD8 + T cells (gift from Dr. Cassian Yee) in a 6-well plate at 1:1 ratio for 4 hr.
Surviving CaSki cells were expanded and termed CaSki P1 cells. containing 1% O 2 , 5% CO 2 , and 94% N 2 at 37°C. Cells were exposed to hypoxia for 14 hr before analysis unless otherwise indicated.
Mice. 6-to 8-week-old female C57BL/6 mice were acquired from Daehan Biolink (Chungbuk, Korea). VEGFA-neutralizing mAb (100ng/ml) was added to cells 24 hr prior to the assay.
Tumor treatment experiments. C57BL/6 mice were inoculated subcutaneously with 10 5 TC-1 P0/no insert or TC-1 P0/HIF-1α cells. For immunization experiments as previously described (14) and P0 cells, indicating that the immune resistance of P3 was not due to antigen loss (14) . Although the HIF family of proteins has been implicated in chemotherapy resistance, its role in resistance to CTLs has not been previously examined under normal oxygen tension (2). We therefore probed for expression of HIF-1α and HIF-2α protein in P0 and P3 cells. Whereas there was no difference in HIF-2α expression between P0 and P3 cells, HIF-1α was up-regulated nearly 20-fold in P3 relative to P0 cells under normoxia; this was confirmed in a clone from the P3 line (A17) ( Figure 1A) . Under hypoxia, HIF-1α expression was also elevated in P3 relative to P0 cells ( Figure 1B) . To verify evolution towards HIF-1α expression under immune surveillance, we measured HIF-1α levels in tumor cells at different stages of selection (P0 to P3). We observed a consistent and gradual increase in HIF-1α from P0 to P3; by contrast, HIF-1α levels remained constant in tumor cells at parallel stages without immune selection (N0 to N3) ( Figure 1C) . We thus conclude that HIF-1α expression is induced in tumor cells by immune selection.
Research. The overexpression of HIF-1α could be either due to elevated synthesis of basal HIF-1α by all tumor cells or to an increase the number of HIF-1α + cells. To address this issue, we labeled P0 to P3 cells with fluorescence-labeled mAb against HIF-1α and determined the frequency of tumor cells with nuclear localization of HIF-1α by fluorescence microscopy. We observed a progressive increase in the frequency of nuclear HIF-1α + tumor cells as immune selection progressed from the P0 to P3 stages (from 10% to 80% of all tumor cells) ( Figure 1D) . Our results therefore demonstrate the molecular evolution of tumor cells towards HIF-1α under the immune selection pressure imposed by vaccination. Author Manuscript Published OnlineFirst on January 14, 2015; DOI: 10.1158/1078-0432.CCR- relative to P0/no insert cells ( Figure 2G) . The presence of HIF-1α also rendered the tumor impervious to adoptive therapy with E7-specific CTLs (Figure 2H) . Notably, there was no significant difference in tumor growth between mice inoculated with P0/HIF-1α and P0/no insert cells without adoptive therapy, suggesting that HIF-1α facilitates cancer progression primarily by promoting immune adaptation.
HIF
HIF-1α turns on an anti-apoptotic network in tumor cells through AKT and ERK signaling.
We hypothesized that HIF-1α may cause immune adaptation by establishing an anti-apoptotic state in tumor cells. To test this, we probed for the expression of a panel of pro-or anti-apoptotic molecules in P3 cells transduced with siHIF-1α (relative to siGFP control) or in P0 cells transduced with HIF-1α (relative to empty vector control). We found that an array of anti-apoptotic molecules, including Bcl-2, Bcl-xL, Bcl-W, XIAP, cIAP1, and cIAP2, were induced by HIF-1α ( Figure 3A) . To elucidate the pathways by which HIF-1α controls expression of these molecules, we measured phosphorylation of AKT, ERK, and P38. We found that HIF-1α drives phosphorylation of AKT and ERK (Figure 3B) , and that pharmacologic inhibition of these pathways strongly reduces expression of anti-apoptotic molecules ( Figure 3C ) and renders tumor cells sensitive to lysis by CTLs ( Figure 3D) . Therefore, HIF-1α-mediated immune adaptation occurs through the AKT and ERK signaling pathways, which trigger the activation of an anti-apoptotic network within tumor cells.
VEGFA ties HIF-1α expression to AKT and ERK signaling.
We next sought to uncover the connection between HIF-1α expression and activation of AKT and ERK signaling. It has previously been shown that HIF-1α drives expression of its key target VEGFA, which is reported to induce the expression of antiapoptotic molecules in tumor cells (17, 18) . We thus measured VEGFA expression and secretion in P0 versus P3 cells, and found both to be over 10-fold higher in P3 relative to P0 cells (Figure 4, A and B) . We confirmed that HIF-1α controls expression of VEGFA by knocking down this transcription factor in P3 Author Manuscript Published OnlineFirst on January 14, 2015; DOI: 10.1158/1078-0432.CCR- cells with siRNA (Figure 4, A and B) , or by introducing it into P0 cells (Figure 4, C and D) . To explore whether VEGFA triggers AKT and ERK signaling and the downstream anti-apoptotic network, we incubated P3 or P0/HIF-1α cells with VEGFA blocking mAb and then measured AKT and ERK phosphorylation, as well as expression of anti-apoptotic molecules. We observed reduced AKT and ERK phosphorylation among P3 or P0/HIF-1α cells incubated with α-VEGFA mAb relative to isotype control, together with lower expression of anti-apoptotic molecules (Figure 4, E and F) . Consistent with this data, P3 and P0/HIF-1α cells incubated with α-VEGFA mAb were more sensitive to killing by E7-specific CTLs compared to cells incubated with isotype control (Figure 4G) . We conclude that a core signaling axis linking HIF-1α, VEGFA, AKT/ERK, and an array of anti-apoptotic molecules drives cancer immune adaptation. Author Manuscript Published OnlineFirst on January 14, 2015; DOI: 10.1158/1078-0432.CCR- selection of parental MDA-MB-231 breast cancer cells or 526mel melanoma cells; we observed HIF-1 overexpression by immune-resistant cells compared to their parental counterparts in both of these systems (data not shown). Consistently, VEGFA mRNA level and protein secretion, AKT and ERK phosphorylation, and expression of the anti-apoptotic factors cIAP-1 and cIAP-2, were up-regulated in P3 cells relative to N3 and P0 cells as well (Figure 5A, 5B, Supplementary Figure 1 and 2 ). These results demonstrate that immune selection induces HIF-1α expression, VEGFA secretion, and activation of the AKT/ERK axis in human cancer cells, which prompts the expression of anti-apoptotic factors. We found 
Discussion
The immune adaption of tumor cells in response to host immune defenses has emerged as a major driving force for cancer onset and progression (19) . This process may occur through host-intrinsic events, such as the induction of tolerance to tumor antigen in tumor-specific CTLs or the recruitment of regulatory T cells or myeloid-derived suppressor cells to the tumor microenvironment (16) .
Alternatively, it may be controlled by tumor-intrinsic events, such as loss of antigen or gain of resistance to apoptosis (17, 18 ).
Here we demonstrate cancer immune adaption in response to a selection pressure imposed by tumorspecific CTLs can be triggered via the HIF-1α/VEGFA pathway.
We found that expression of HIF-1α is profoundly up-regulated in tumor cells subjected to immune Author Manuscript Published OnlineFirst on January 14, 2015; DOI: 10.1158/1078-0432.CCR- expression is frequently high in these areas. However, our data suggest that HIF-1 expression is not only limited to the core of the tumor mass but may also extend into the marginal areas of the tumor (which have normal oxygen tension). What would be the benefit for tumor cells of HIF-1 expression in these areas? We believe that, since tumor cells in the periphery are the first to encounter infiltrating lymphocytes, these cells would be the most susceptible to immune attack. Therefore, gain of HIF-1 by these marginal tumor cells would confer a strong 'fitness' advantage, potentially explaining the evolution of tumor cells towards HIF-1 expression even under normoxia in response to an immune selection pressure. Independently, HIF-1 expression under normoxia would induce VEGF secretion and promote angiogenesis, thereby contributing to tumor progression (3, 23) . For instance, HIF-1α under normoxia has been implicated in patients with highly vascularized hemangioblastoma, in which tumor cells immediately adjacent to blood vessels were found to stain intensely for HIF-1 (3, 23, 24) . Future work should aim to explore these theories.
Finally, it is intriguing to consider our results in light of the "adaptation model" of the immune system that has been recently proposed (25) , in which the expression of certain receptors and corresponding ligands by immune cells or peripheral tissue cells tunes the magnitude of the immune response. In this context, HIF-1 may represent an adaptation-inducing factor that turns on the expression of ligands which directly modulate lymphocyte activation. This will be an interesting area for future investigation.
In conclusion, our study unravels a signaling pathway comprised of VEGFA, AKT/ERK, and anti-apoptotic Author Manuscript Published OnlineFirst on January 14, 2015; DOI: 10.1158/1078-0432.CCR- 
